Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis

Lucia Masarova, Ahmad Alhuraiji, Prithviraj Bose, Naval Daver, Naveen Pemmaraju, Jorge Cortes, Sherry Pierce, Hagop Kantarjian, Srdan Verstovsek

Research output: Contribution to journalArticle

Abstract

Severe thrombocytopenia (platelets <50 × 109/L) is associated with very poor outcome of patients with myelofibrosis (MF). As patients with primary myelofibrosis (PMF) differ from patients with postessential thrombocythemia (PET-MF) and postpolycythemia vera myelofibrosis (PPV-MF), we aimed to evaluate the significance of low platelets among these patients. We present clinical characteristics and outcome of patients with either PMF, PPV-MF, or PET-MF, and thrombocytopenia who presented to our institution between 1984 and 2015. Of 1269 patients (877 PMF, 212 PPV-MF, 180 PET-MF), 11% and 14% had platelets either <50 × 109/L or between 50-100 × 109/L, respectively. Patients with platelets <50 × 109/L were most anemic and transfusion dependent, had highest blast count and unfavorable karyotype. In general, their overall and leukemia-free survival was the shortest with median time of 15 and 13 months, respectively; with incidence of acute leukemia almost twice as high as in the remaining patients (6.9 vs 3.6 cases per 100 person-years). Nevertheless, this observation remains mostly significant for patients with PMF, as those with PEV/PVT-MF have already significantly inferior prognosis with platelets <100 × 109/L.

Original languageEnglish (US)
Pages (from-to)257-263
Number of pages7
JournalEuropean Journal of Haematology
Volume100
Issue number3
DOIs
StatePublished - Mar 2018

Fingerprint

Essential Thrombocythemia
Polycythemia Vera
Primary Myelofibrosis
Thrombocytopenia
Blood Platelets
Leukemia
Thrombocytosis
Karyotype

Keywords

  • outcome
  • postessential thrombocythemia myelofibrosis
  • postpolycythemia vera myelofibrosis
  • primary myelofibrosis
  • thrombocytopenia

ASJC Scopus subject areas

  • Hematology

Cite this

Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis. / Masarova, Lucia; Alhuraiji, Ahmad; Bose, Prithviraj; Daver, Naval; Pemmaraju, Naveen; Cortes, Jorge; Pierce, Sherry; Kantarjian, Hagop; Verstovsek, Srdan.

In: European Journal of Haematology, Vol. 100, No. 3, 03.2018, p. 257-263.

Research output: Contribution to journalArticle

Masarova, L, Alhuraiji, A, Bose, P, Daver, N, Pemmaraju, N, Cortes, J, Pierce, S, Kantarjian, H & Verstovsek, S 2018, 'Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis', European Journal of Haematology, vol. 100, no. 3, pp. 257-263. https://doi.org/10.1111/ejh.13005
Masarova, Lucia ; Alhuraiji, Ahmad ; Bose, Prithviraj ; Daver, Naval ; Pemmaraju, Naveen ; Cortes, Jorge ; Pierce, Sherry ; Kantarjian, Hagop ; Verstovsek, Srdan. / Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis. In: European Journal of Haematology. 2018 ; Vol. 100, No. 3. pp. 257-263.
@article{ffd9bc5cb50a4ed8b50e2feb9d98594f,
title = "Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis",
abstract = "Severe thrombocytopenia (platelets <50 × 109/L) is associated with very poor outcome of patients with myelofibrosis (MF). As patients with primary myelofibrosis (PMF) differ from patients with postessential thrombocythemia (PET-MF) and postpolycythemia vera myelofibrosis (PPV-MF), we aimed to evaluate the significance of low platelets among these patients. We present clinical characteristics and outcome of patients with either PMF, PPV-MF, or PET-MF, and thrombocytopenia who presented to our institution between 1984 and 2015. Of 1269 patients (877 PMF, 212 PPV-MF, 180 PET-MF), 11{\%} and 14{\%} had platelets either <50 × 109/L or between 50-100 × 109/L, respectively. Patients with platelets <50 × 109/L were most anemic and transfusion dependent, had highest blast count and unfavorable karyotype. In general, their overall and leukemia-free survival was the shortest with median time of 15 and 13 months, respectively; with incidence of acute leukemia almost twice as high as in the remaining patients (6.9 vs 3.6 cases per 100 person-years). Nevertheless, this observation remains mostly significant for patients with PMF, as those with PEV/PVT-MF have already significantly inferior prognosis with platelets <100 × 109/L.",
keywords = "outcome, postessential thrombocythemia myelofibrosis, postpolycythemia vera myelofibrosis, primary myelofibrosis, thrombocytopenia",
author = "Lucia Masarova and Ahmad Alhuraiji and Prithviraj Bose and Naval Daver and Naveen Pemmaraju and Jorge Cortes and Sherry Pierce and Hagop Kantarjian and Srdan Verstovsek",
year = "2018",
month = "3",
doi = "10.1111/ejh.13005",
language = "English (US)",
volume = "100",
pages = "257--263",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis

AU - Masarova, Lucia

AU - Alhuraiji, Ahmad

AU - Bose, Prithviraj

AU - Daver, Naval

AU - Pemmaraju, Naveen

AU - Cortes, Jorge

AU - Pierce, Sherry

AU - Kantarjian, Hagop

AU - Verstovsek, Srdan

PY - 2018/3

Y1 - 2018/3

N2 - Severe thrombocytopenia (platelets <50 × 109/L) is associated with very poor outcome of patients with myelofibrosis (MF). As patients with primary myelofibrosis (PMF) differ from patients with postessential thrombocythemia (PET-MF) and postpolycythemia vera myelofibrosis (PPV-MF), we aimed to evaluate the significance of low platelets among these patients. We present clinical characteristics and outcome of patients with either PMF, PPV-MF, or PET-MF, and thrombocytopenia who presented to our institution between 1984 and 2015. Of 1269 patients (877 PMF, 212 PPV-MF, 180 PET-MF), 11% and 14% had platelets either <50 × 109/L or between 50-100 × 109/L, respectively. Patients with platelets <50 × 109/L were most anemic and transfusion dependent, had highest blast count and unfavorable karyotype. In general, their overall and leukemia-free survival was the shortest with median time of 15 and 13 months, respectively; with incidence of acute leukemia almost twice as high as in the remaining patients (6.9 vs 3.6 cases per 100 person-years). Nevertheless, this observation remains mostly significant for patients with PMF, as those with PEV/PVT-MF have already significantly inferior prognosis with platelets <100 × 109/L.

AB - Severe thrombocytopenia (platelets <50 × 109/L) is associated with very poor outcome of patients with myelofibrosis (MF). As patients with primary myelofibrosis (PMF) differ from patients with postessential thrombocythemia (PET-MF) and postpolycythemia vera myelofibrosis (PPV-MF), we aimed to evaluate the significance of low platelets among these patients. We present clinical characteristics and outcome of patients with either PMF, PPV-MF, or PET-MF, and thrombocytopenia who presented to our institution between 1984 and 2015. Of 1269 patients (877 PMF, 212 PPV-MF, 180 PET-MF), 11% and 14% had platelets either <50 × 109/L or between 50-100 × 109/L, respectively. Patients with platelets <50 × 109/L were most anemic and transfusion dependent, had highest blast count and unfavorable karyotype. In general, their overall and leukemia-free survival was the shortest with median time of 15 and 13 months, respectively; with incidence of acute leukemia almost twice as high as in the remaining patients (6.9 vs 3.6 cases per 100 person-years). Nevertheless, this observation remains mostly significant for patients with PMF, as those with PEV/PVT-MF have already significantly inferior prognosis with platelets <100 × 109/L.

KW - outcome

KW - postessential thrombocythemia myelofibrosis

KW - postpolycythemia vera myelofibrosis

KW - primary myelofibrosis

KW - thrombocytopenia

UR - http://www.scopus.com/inward/record.url?scp=85042093703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042093703&partnerID=8YFLogxK

U2 - 10.1111/ejh.13005

DO - 10.1111/ejh.13005

M3 - Article

C2 - 29226426

AN - SCOPUS:85042093703

VL - 100

SP - 257

EP - 263

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 3

ER -